New and promising immune oncology drugs combinations



Given that no new immunotherapeutic drugs proved to be at least as effective as approved CTLA-4 and PD-1/PD-L1 inhibitors during last years the focus of further immuno oncology (IO)development has shifted to the research on different drug combinations. Most of new immunotherapeutics are studied in combinations with PD-1/PD-L1 inhibitors. This paper reviews most perspective targets for therapeutic manipulations currently studied in combinations with immune check-point inhibitors, such as Tim-3, LAG-3, TIGIT, OX-40, 4-1BB, STING, TGF-β, as well as some metabolic pathways. Also the principles of individualized biology-tailored approaches to IO drugs combining are discussed.